Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease Moderate
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic…
- Trial name
- NCT03028142
- Testing
- 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium
- Volunteers
- 30 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01694771
- Testing
- Tiotropium, Olodaterol
- Where
- 90 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
The study is intended to assess the relative bioavailability of 2 different abediterol nebulised formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04199598
- Testing
- Abediterol (2.4 μg), Abediterol (4.8 μg), Abediterol (2.5 μg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
Chronic Obstructive Lung Disease, Interstitial Lung Disease
Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease
A preliminary study to evaluate a new nasal interface and portable ventilator system in comparison to standard oxygen therapy in patients with severe chronic lung disease.
- Trial name
- NCT02278107
- Testing
- Tidal Assist Ventilator System, Nasal Cannula Oxygen
- Volunteers
- 20 people
- Sponsor
- New Aera, Inc
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to…
- Trial name
- XYP-202401 (NCT06754865)
- Testing
- Xiyanping injection+ antibiotic, Antibiotic
- Volunteers
- 1,140 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Chronic Obstructive Pulmonary Disease
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice…
- Trial name
- NCT06545500
- Testing
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg)
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD.
- Trial name
- NCT00500318
- Testing
- Aclidinium Bromide
- Where
- 52 sites in United States, Canada
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by inflammation-mediated damage to lung tissue.
- Trial name
- NCT01387178
- Testing
- fluticasone propionate/salmeterol 250µg/50µg (FSC), tiotropium bromide (TIO)
- Volunteers
- 22,223 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
MoblO2 to Maintain Oxygenation
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course.
- Trial name
- SSeifert (NCT07704567)
- Testing
- MoblO2 controls O2 flow, MoblO2 does not control flow
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Minnesota HealthSolutions
Pulmonary Disease, Chronic Obstructive
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease
- Trial name
- NCT00929851
- Testing
- CHF1535, Formoterol fumarate
- Where
- United Kingdom
- Volunteers
- 1,199 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65…
- Conditions
- Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
- Trial name
- NCT04647383
- Testing
- Lemborexant 10 mg
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Pulmonary Disease, Chronic Obstructive
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the…
- Trial name
- NCT03964207
- Testing
- Tiotropium Respimat® (T1), Tiotropium Handihaler® (T2)
- Where
- 8 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD.
- Trial name
- Navigator (NCT07684820)
- Testing
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 600 people
- Sponsor
- Expedition Therapeutics, Inc
Chronic Obstructive Pulmonary Disease, Dyspnea
A Wearable In-phase Chest Wall Vibration Device for Relief of Dyspnoea in COPD: a First-in-human Exploratory Study
The goal of this exploratory clinical trial is to evaluate the initial clinical safety and performance of a prototype wearable chest wall vibration (CWV) device intended to relieve exertional dyspnea in adults with Chronic…
- Trial name
- ResWave (NCT06432920)
- Testing
- ResWave
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Elevre Medical Ltd.
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
- Trial name
- TERRANOVA (NCT02155660)
- Testing
- Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 2,255 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.